COVID-19 and Its Impact on the Foot and Lower Limb

Since its emergence in late 2019, the SARS-CoV-2 virus has profoundly affected nearly every system in the human body. While much attention has focused on respiratory and cardiovascular complications, the foot and lower limb have emerged as critical areas of clinical concern. From acute thrombotic events to chronic post-COVID complications, COVID-19 presents a multifaceted challenge to lower limb health that spans both the acute infection phase and the extended recovery period.

Acute Vascular Complications

One of the most alarming aspects of COVID-19’s impact on the lower extremities is its ability to induce a hypercoagulable state. The virus triggers an excessive inflammatory response and directly damages endothelial cells, leading to increased thrombotic risk. Deep vein thrombosis (DVT) in the legs has emerged as a frequent complication, particularly in hospitalized patients. Studies have documented DVT incidence rates ranging from 20% to 30% in critically ill COVID-19 patients, significantly higher than in other acute illness populations.

The pathophysiology involves multiple mechanisms: viral-induced endothelial dysfunction, increased platelet aggregation, elevated levels of tissue factor, and prolonged immobilization in intensive care units. Patients often present with unilateral leg swelling, pain, and erythema. The consequences can be severe, with pulmonary embolism occurring in a substantial proportion of cases, emphasizing the necessity for vigilant monitoring and anticoagulation protocols. Even non-hospitalized patients have experienced unexpected DVT events, suggesting that COVID-19’s prothrombotic effects extend beyond critical illness.

Arterial Insufficiency and Limb Ischemia

Beyond venous thrombosis, COVID-19 has demonstrated an alarming propensity for acute arterial thrombosis affecting the lower limbs. Case reports and series have documented acute limb ischemia requiring emergency vascular intervention, sometimes resulting in amputation. This arterial involvement likely stems from the same endothelial damage and hypercoagulable state that promotes venous thrombosis, but its consequences can be more immediately catastrophic.

The mechanism appears to involve both macro and microvasculature damage. Histopathological examinations have revealed extensive thrombosis of small vessels throughout affected tissues, a phenomenon termed “complement-driven microvascular thrombosis.” In the foot and lower leg, this can manifest as digital necrosis, tissue gangrene, and skin manifestations resembling frostbite. Some patients have experienced purple discoloration of toes and feet—phenomena documented even in patients without severe systemic COVID-19 infection, suggesting that localized vascular pathology can occur relatively independently of disease severity.

Myalgias and Musculoskeletal Pain

Beyond vascular complications, COVID-19 frequently triggers lower limb myalgias. Studies indicate that muscle pain affects 30-50% of COVID-19 patients, with lower extremity involvement being particularly common. These myalgias likely result from viral myositis, inflammatory mediator production, and immune system activation. Patients report severe leg pain, weakness, and difficulty ambulating during acute illness.

The virus has been detected in muscle tissue, suggesting direct viral invasion may contribute to inflammation. Additionally, the production of pro-inflammatory cytokines—including IL-6, TNF-alpha, and IL-1—during COVID-19 infection creates an inflammatory milieu that exacerbates muscle pain and dysfunction. For some patients, these myalgias persist weeks or months beyond viral clearance, contributing to prolonged disability.

Long COVID and Persistent Lower Limb Symptoms

Perhaps most significantly for long-term patient outcomes, a substantial proportion of COVID-19 survivors develop persistent lower limb symptoms characterized as Long COVID or Post-Acute Sequelae of COVID-19 (PASC). Patients report ongoing leg pain, weakness, cramping, and reduced functional capacity months after initial infection. Some experience persistent swelling, tingling, or numbness in the feet suggesting nerve involvement.

The etiology of Long COVID lower limb symptoms remains incompletely understood but likely involves multiple mechanisms: persistent viral proteins or viral RNA in tissues, ongoing microvascular dysfunction, autonomic nervous system dysregulation, and chronic inflammatory state. Many patients develop reduced exercise tolerance, with exertion leading to disproportionate fatigue and leg symptom exacerbation—a phenomenon termed “post-exertional malaise.” This significantly limits rehabilitation and return to normal activities.

Neurological Manifestations

COVID-19-associated neurological complications extend to the peripheral nervous system, affecting foot and lower limb sensation and function. Guillain-Barré syndrome (GBS), a rare autoimmune condition affecting peripheral nerves, has been reported in COVID-19 patients, causing leg weakness and potential paralysis. Additionally, reports of other neuropathies, including small fiber neuropathy affecting pain and temperature sensation in the feet, have emerged.

The mechanism likely involves molecular mimicry, where antibodies generated against SARS-CoV-2 antigens cross-react with nerve antigens, triggering inflammatory demyelination. Patients experience progressive weakness, often ascending from lower limbs, along with sensory symptoms. Recovery can be prolonged, and some patients experience persistent disability.

Clinical Management and Rehabilitation

Managing COVID-19-related lower limb complications requires a multidisciplinary approach. Acute thrombotic complications necessitate prompt anticoagulation and potential thromboembolic intervention. Patients require serial assessments for signs of compartment syndrome or tissue ischemia demanding surgical decompression or amputation.

For chronic lower limb manifestations, rehabilitation plays a crucial role. Physical therapy addressing weakness, deconditioning, and mobility limitations is essential. However, care must be taken with exercise prescription, as aggressive rehabilitation can exacerbate symptoms in Long COVID patients. A graduated approach with careful monitoring is preferred. Some patients benefit from compression therapy for persistent swelling, while others require pharmacological management of neuropathic pain.

COVID-19’s impact on the foot and lower limb encompasses a remarkable spectrum of pathology, from acute life-threatening vascular complications to chronic debilitating symptoms affecting millions of survivors worldwide. The virus’s ability to trigger thrombotic states, damage endothelial cells, provoke myositis, and trigger neurological complications creates a perfect storm for lower extremity morbidity.

As the pandemic evolves and our understanding deepens, recognition of these lower limb manifestations becomes increasingly important for clinicians. Patients presenting with unexplained leg symptoms, thrombosis, or limb ischemia should be evaluated with COVID-19 as a potential etiology. Furthermore, the substantial proportion of Long COVID patients with persistent lower limb symptoms highlights the need for ongoing research, rehabilitation protocols, and support systems. The foot and lower limb, often overlooked in discussions of COVID-19 complications, represent a critical frontier in understanding this virus’s full pathological impact on human health.